Valeurs seuils pour le rapport coût-efficacité en soins de santé - KCE

68 ICER Thresholds KCE Reports 100
150. Towse A, Pritchard C. Does NICE have a threshold? An external view. In: Towse A, Pritchard
C, Devlin N, editors. Cost-Effectiveness Thresholds. Economic and Ethical Issues. London:
King’s Fund and Office of Health Economics; 2002.
151. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. April
2004.
152. NICE. Guide to the Methods of Technology Appraisal. Draft for consultation. 2007 November
2007.
153. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology
Appraisal. Draft for Consultation. London: NICE; 2007 November 2007. Available from:
http://www.nice.org.uk/media/8AE/5C/TAMethodsGuideUpdateFINALFORCONSULTATION2
81107.pdf
154. Guidelines for the economic evaluation of health technologies: Canada (3rd edition). In.
Ottawa: Canadian Agency for Drugs and Technologies in Health; 2006.
155. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to
be to warrant adoption and utilization? Tentative guidelines for using clinical and economic
evaluations. CMAJ. 1992;146(4):473-81.
156. Raad voor de Volksgezondheid en Zorg. Zinnige en duurzame zorg. Zoetermeer: 2006.
Available from: http://www.rvz.net/data/download/advies_Zinnige_zorg.pdf
157. Stolk EA, Poley M, Brouwer W, van Busschbach J. Proeftoetsing van het iMTA-model.
Identificatie van aandoeningen met minimale ziektelast en proeftoetsing van de voor ziektelast
gecorrigeerde doelmatigheidstoets. In: (CVZ) CvZ, editor. Vervolgonderzoek breedte
geneesmiddelenpakket. Amstelveen; 2002. Available from:
158.
http://www.xs4all.nl/~jannetvb/busschbach/manuscripts/2002%20Vervolgonderzoek%20CvZ.pdf
Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a qualityadjusted
life year: in search of a standard. Med Decis Making. 2000;20(3):332-42.
159. Grocott R, Schoeler R, Priest V, Hall C, Metcalfe S, Brougham M, et al. Prescription for
Pharmacoeconomic Analysis. Methdos for cost-utility analysis. 2007.
160. PHARMAC. Prescription for pharmacoeconomic analysis: methods for cost-utility analysis.
Pharmaceutical Management Agency; 2007.
161. The Pharmaceutical Benefits Board. General guidelines for economic evaluations from the
Pharmaceutical Benefits Board. LFNAR; 2003. (2003:2) Available from:
162.
http://www.lfn.se/upload/English/ENG_lfnar2003-eng.pdf
Carlsson P. Health technology assessment and priority setting for health policy in Sweden. Int J
Technol Assess Health Care. 2004;20(1):44-54.
163. Norwegian Medicines Agency Oslo;c 2005. Norwegian guidelines for pharmacoeconomic
analysis in connection with applications for reimbursement. Available from:
http://www.legemiddelverket.no/templates/InterPage____25644.aspx?filterBy=CopyToIndustry
164. Kristensen FB, Sigmund He. Health Technology Assessment Handbook. 2nd edition ed.
Copenhagen: Danish Centre for Health Technology Assessment, National Board of Health;
2007.
165. Royal Decree of 21 December 2001. Koninklijk Besluit tot vaststelling van de procedures,
termijnen en voorwaarden inzake de tegemoetkoming van de verplichte verzekering voor
geneeskundige verzorging en uitkeringen in de kosten van farmaceutische specialiteiten/Arrêté
Royal fixant les procédures, delais et conditions en matière d’intervention de l’assurance
obligatoire soins de santé et indemnités dans le coût des spécialités pharmaceutiques. Belgisch
Staatsblad/Moniteur Belge 29/12/2001: .
166. Royal Decree of 21 December 2001. Koninklijk besluit tot wijziging van het koninklijk besluit
van 3 juli 1996 tot uitvoering van de wet betreffende de verplichte verzekering voor
geneeskundige verzorging en uitkeringen, gecoördineerd op 14 juli 1994/ Arrêté Royal portant
modification de l’arrêté Royal du 3 juillet 1996 portant exécution de la loi relative à l’assurance
obligatoire soins de santé et indemnités, coordonnée le 14 juillet 1994. . Belgisch
Staatsblad/Moniteur Belge 29/12/2001.
167. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures
regulating the pricing of medicinal products for human use and their inclusion in the scope of
national health insurance systems. OJ No L 40, 1989. Available from:
http://ec.europa.eu/enterprise/phabiocom/docs/dir_1989_105/dir_1989_105_en.pdf